Author/Authors :
Komur، Suheyla نويسنده Department of Infectious Diseases, Cukurova University, Adana, Turkey Komur, Suheyla , Kurtaran، Behice نويسنده Department of Infectious Diseases, Cukurova University, Adana, Turkey Kurtaran, Behice , Seza Inal، Ayse نويسنده Department of Infectious Diseases, Cukurova University, Adana, Turkey Seza Inal, Ayse , Pullukcu، Husnu نويسنده Department of Infectious Diseases, Ege University, Izmir, Turkey Pullukcu, Husnu , Ulu، Aslihan نويسنده Department of Infectious Diseases, Cukurova University, Adana, Turkey Ulu, Aslihan , Kuscu، Ferit نويسنده Numune Training and Research Hospital, Adana, Turkey Kuscu, Ferit , Yamazhan، Tansu نويسنده Department of Infectious Diseases, Ege University, Izmir, Turkey Yamazhan, Tansu , Tasova، Yesim نويسنده Department of Infectious Diseases, Cukurova University, Adana, Turkey Tasova, Yesim , Zeki Aksu، Hasan Salih نويسنده Department of Infectious Diseases, Cukurova University, Adana, Turkey Zeki Aksu, Hasan Salih
Abstract :
In patients with chronic hepatitis C, triple drug regimens containing a protease inhibitor, peginterferon and ribavirin were found to significantly increase sustained virologic response rates compared to dual drug regimen containing pegylated interferon and ribavirin, especially in genotype 1. In Turkey, telaprevir has been used since March 2013. We aimed to evaluate results of patients with chronic hepatitis C treated with telaprevir, peginterferon and ribavirin. We evaluated 28 patients with genotype 1 chronic hepatitis C infection treated with triple drug regimen containing telaprevir, in three medical centers in Turkey, retrospectively. Demographic data of patients, treatment indications, adverse events and outcomes were recorded. Of 28 patients intended to treat, 25 (89.2%) patients completed the treatment. Overall, 21 (82.1%) patients had relapse and five patients were non-responder. Regarding the treatment outcomes of Telaprevir based regimen, 20/26 patients achieved sustained virological response. Pruritus, rash, dysgeusia, anorectal discomfort and anemia were main adverse effects. Blood transfusion and ribavirin dose reduction required for 7 and 11 patients, respectively. Due to several adverse effects, 10 patients were hospitalized. Although more frequent and severe adverse effects, telaprevir has been promising for patients with treatment-experienced hepatitis C.
